Combination Cancer Immunotherapy Expand Treatment Options in Breast Cancer

Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:

 

• Global & Regional Combination Cancer Immunotherapy Market Insight Till 2028
• Global Combination Cancer Immunotherapy Market Opportunity: > USD 12 Billion
• Combination Cancer Immunotherapy Market By Different Cancers
• Patent, Price & Dosage Analysis On Approved Combination Drugs
• Global & Regional Sales Insights On Approved Combination Drugs Till 2028
• Insight on 600 Combination Cancer Immunotherapy Drugs In Clinical Trials
• Insight on 45 Combination Cancer Immunotherapy Drugs Commercially Approved In Market
• Clinical Trials & Patent Insight By Company, Country, Indication & Phase

 

 

Download Report:

 

https://www.kuickresearch.com/report-combination-cancer-therapy-market

 

In recent times, immunotherapy has emerged out to be most exciting paradigm change in cancer treatment. Since its initial approval in breast cancer, it has become the standard mode of treatment for wide subtypes of breast cancer. Due to their targeted nature and less associated side effects, pharmaceutical companies have invested huge amount to develop novel immunotherapeutic approaches in cancer treatment. However, it has been demonstrated that limited survival outcomes are associated with utilization of immunotherapy as monotherapy. Therefore, researchers believed that combination of immunotherapy with other conventional or targeted therapies will enhance the outcomes in breast cancer patients. This has led to flurry of clinical trials across various subtypes of breast cancer.

 

In 2021, US FDA granted approval to Keytruda in combination with chemotherapy for the management of high-risk early-stage triple-negative breast cancer. Further, this novel combination was granted approval by European Commission in 2022. The approval was based on the promising results from the phase-III KEYNOTE-522 trial which demonstrated that the Keytruda in combination with chemotherapeutic drugs (carboplatin and paclitaxel, followed by doxorubicin or epirubicin and cyclophosphamide) has significantly enhanced the progression free survival rate and has a significant reduction in tumor size in comparison to monotherapy. Apart from this, regulatory bodies have also approved tecentriq in combination with abraxane and Herceptin hylecta for the management of breast cancer.

 

The rising incidences of breast cancer associated with the encouraging response of combination cancer immunotherapy have attracted pharmaceutical investments in this domain. For instance in 2021, HiberCell announced collaboration with Merck to evaluate Keytruda in combination with HiberCell’s odetiglucan (Imprime PGG), a Dectin-1, pattern recognition receptor agonist. The collaboration will conduct phase-II single arm, open-label clinical trial which is anticipated to enroll 50 patients with metastatic breast cancer who have progressed through prior hormone therapy with at least one CDK4/6 inhibitor in sites across the United States. In addition, Alphamab Oncology is also conducting phase-II study of KN026 (HER2 bispecific antibody) combined with KN046 (PD-L1/CTLA-4 bispecific antibody) in patients with HER2 positive breast cancer.  

 

Moreover, US FDA has also accepted the investigational new drug application Cytovation, thus allowing the drug to proceed to phase-II studies evaluating CyPep-1 in combination with pembrolizumab for advanced solid tumors including triple negative breast cancer. The study will also be conducted across various sites in Europe, primarily in Spain, Netherlands, France, and Italy. CyPep-1 is an investigational first in class targeted tumor membrane immunotherapy engineered to selectively target cancer cells.

 

The progress in science and identification of novel targets in breast cancer will also open new avenues in the market. The immunotherapy pipeline for breast cancer is highly concentrated and consists of several next generation therapeutics including bispecific antibodies, CAR T cell therapies, antibody drug conjugates, and others. The forthcoming years will witness new product launches for breast cancer management, which will boost the growth of market. The introduction of these drugs in the market will also gain interest as combination therapy, thus propelling the growth of market.

 

As per our report findings, the global breast combination cancer immunotherapy market is expected to surpass US$ 2 Billion by 2028 which is mainly due to rising awareness about the availability of targeted immunotherapy among breast cancer patients. As more patients are diagnosed with breast cancer, the need for accurate and targeted therapy increases thus surging the research and investment in this domain. The key players in breast cancer combination immunotherapy segment are Zymeworks, ALX Oncology, Alphamab Oncology, Sanofi, Merck, Ambrx Biopharma and several others. The strong pipeline of combination immunotherapy of these companies also suggests promising future of combination immunotherapy in breast cancer market.   

 

 Contact:

 

Neeraj Chawla

Kuick research

Research Head

+91-981410366

neeraj@kuickresearch.com

https://www.kuickresearch.com